BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Park VS, Pursell ZF. POLE proofreading defects: Contributions to mutagenesis and cancer. DNA Repair (Amst) 2019;76:50-9. [PMID: 30818169 DOI: 10.1016/j.dnarep.2019.02.007] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 5.0] [Reference Citation Analysis]
Number Citing Articles
1 Yuan H, Ji J, Shi M, Shi Y, Liu J, Wu J, Yang C, Xi W, Li Q, Zhu W, Li J, Gong X, Zhang J. Characteristics of Pan-Cancer Patients With Ultrahigh Tumor Mutation Burden. Front Oncol 2021;11:682017. [PMID: 33968789 DOI: 10.3389/fonc.2021.682017] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Park VS, Sun MJS, Frey WD, Williams LG, Hodel KP, Strauss JD, Wellens SJ, Jackson JG, Pursell ZF. Mouse model and human patient data reveal critical roles for Pten and p53 in suppressing POLE mutant tumor development. NAR Cancer 2022;4:zcac004. [PMID: 35252866 DOI: 10.1093/narcan/zcac004] [Reference Citation Analysis]
3 Li Y, Bian Y, Wang K, Wan XP. POLE mutations improve the prognosis of endometrial cancer via regulating cellular metabolism through AMF/AMFR signal transduction. BMC Med Genet 2019;20:202. [PMID: 31864301 DOI: 10.1186/s12881-019-0936-2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
4 Hodel KP, Sun MJS, Ungerleider N, Park VS, Williams LG, Bauer DL, Immethun VE, Wang J, Suo Z, Lu H, McLachlan JB, Pursell ZF. POLE Mutation Spectra Are Shaped by the Mutant Allele Identity, Its Abundance, and Mismatch Repair Status. Mol Cell 2020;78:1166-1177.e6. [PMID: 32497495 DOI: 10.1016/j.molcel.2020.05.012] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
5 Gorlov IP, Amos CI, Tsavachidis S, Begg C, Hernando E, Cheng C, Shen R, Orlow I, Luo L, Ernstoff MS, Parker J, Thomas NE, Gorlova OY, Berwick M. Human genes differ by their UV sensitivity estimated through analysis of UV-induced silent mutations in melanoma. Hum Mutat 2020;41:1751-60. [PMID: 32643855 DOI: 10.1002/humu.24078] [Reference Citation Analysis]
6 Leskela S, Romero I, Rosa-Rosa JM, Caniego-Casas T, Cristobal E, Pérez-Mies B, Gutierrez-Pecharroman A, Santón A, Ojeda B, López-Reig R, Palacios-Berraquero ML, Andrada E, Montes S, Pastor F, Gomez MC, López-Guerrero JA, Poveda A, Palacios J. Molecular Heterogeneity of Endometrioid Ovarian Carcinoma: An Analysis of 166 Cases Using the Endometrial Cancer Subrogate Molecular Classification. Am J Surg Pathol 2020;44:982-90. [PMID: 32384322 DOI: 10.1097/PAS.0000000000001478] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 4.5] [Reference Citation Analysis]
7 Zahurancik WJ, Suo Z. Kinetic investigation of the polymerase and exonuclease activities of human DNA polymerase ε holoenzyme. J Biol Chem 2020;295:17251-64. [PMID: 33051204 DOI: 10.1074/jbc.RA120.013903] [Reference Citation Analysis]
8 Robert J. [Genomic instability, the engine of oncogenesis]. Bull Cancer 2021;108:38-40. [PMID: 33187684 DOI: 10.1016/j.bulcan.2020.10.006] [Reference Citation Analysis]
9 Zeng Z, Yang B, Liao Z. Biomarkers in Immunotherapy-Based Precision Treatments of Digestive System Tumors. Front Oncol 2021;11:650481. [PMID: 33777812 DOI: 10.3389/fonc.2021.650481] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
10 Garmezy B, Gheeya J, Lin HY, Huang Y, Kim T, Jiang X, Thein KZ, Pilié PG, Zeineddine F, Wang W, Shaw KR, Rodon J, Shen JP, Yuan Y, Meric-Bernstam F, Chen K, Yap TA. Clinical and Molecular Characterization of POLE Mutations as Predictive Biomarkers of Response to Immune Checkpoint Inhibitors in Advanced Cancers. JCO Precis Oncol 2022;6:e2100267. [PMID: 35108036 DOI: 10.1200/PO.21.00267] [Reference Citation Analysis]
11 Pavlov YI, Zhuk AS, Stepchenkova EI. DNA Polymerases at the Eukaryotic Replication Fork Thirty Years after: Connection to Cancer. Cancers (Basel) 2020;12:E3489. [PMID: 33255191 DOI: 10.3390/cancers12123489] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
12 Ottini A, Sepe P, Beninato T, Claps M, Guadalupi V, Verzoni E, Giannatempo P, Baciarello G, de Braud F, Procopio G. Biomarker-driven immunotherapy for precision medicine in prostate cancer. Per Med 2022;19:51-66. [PMID: 34873959 DOI: 10.2217/pme-2021-0079] [Reference Citation Analysis]
13 Stasenko M, Tunnage I, Ashley CW, Rubinstein MM, Latham AJ, Da Cruz Paula A, Mueller JJ, Leitao MM Jr, Friedman CF, Makker V, Soslow RA, DeLair DF, Hyman DM, Zamarin D, Alektiar KM, Aghajanian CA, Abu-Rustum NR, Weigelt B, Cadoo KA. Clinical outcomes of patients with POLE mutated endometrioid endometrial cancer. Gynecol Oncol 2020;156:194-202. [PMID: 31757464 DOI: 10.1016/j.ygyno.2019.10.028] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
14 Yang Y, Jain RK, Glenn ST, Xu B, Singh PK, Wei L, Hu Q, Long M, Hutson N, Wang J, Battaglia S, George S. Complete response to anti-PD-L1 antibody in a metastatic bladder cancer associated with novel MSH4 mutation and microsatellite instability. J Immunother Cancer 2020;8:e000128. [PMID: 32221012 DOI: 10.1136/jitc-2019-000128] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
15 Dong S, Zakaria H, Hsiehchen D. Non-Exonuclease Domain POLE Mutations Associated with Immunotherapy Benefit. The Oncologist 2022. [DOI: 10.1093/oncolo/oyac017] [Reference Citation Analysis]
16 Xing X, Jin N, Wang J. Polymerase Epsilon-Associated Ultramutagenesis in Cancer. Cancers 2022;14:1467. [DOI: 10.3390/cancers14061467] [Reference Citation Analysis]
17 Li S, Shi B, Liu X, An HX. Acetylation and Deacetylation of DNA Repair Proteins in Cancers. Front Oncol 2020;10:573502. [PMID: 33194676 DOI: 10.3389/fonc.2020.573502] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
18 Deshmukh AL, Porro A, Mohiuddin M, Lanni S, Panigrahi GB, Caron MC, Masson JY, Sartori AA, Pearson CE. FAN1, a DNA Repair Nuclease, as a Modifier of Repeat Expansion Disorders. J Huntingtons Dis 2021;10:95-122. [PMID: 33579867 DOI: 10.3233/JHD-200448] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
19 Wu X, Tang H, Xu WH, Tang H, Wei S, Anwaier A, Huang H, Qu YY, Zhang H, Zhao S, Li H, Liu W, Chen H, Ding C, Ye D. Protumorigenic Role of Elevated Levels of DNA Polymerase Epsilon Predicts an Immune-Suppressive Microenvironment in Clear Cell Renal Cell Carcinoma. Front Genet 2021;12:751977. [PMID: 34950188 DOI: 10.3389/fgene.2021.751977] [Reference Citation Analysis]
20 Hu H, Cai W, Wu D, Hu W, Dong Wang L, Mao J, Zheng S, Ge W. Ultra-mutated colorectal cancer patients with POLE driver mutations exhibit distinct clinical patterns. Cancer Med 2021;10:135-42. [PMID: 33125191 DOI: 10.1002/cam4.3579] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
21 Wang D, Zhang Y, li R, Li J, Zhang R. Consistency and reproducibility of large panel next-generation sequencing: multi-laboratory assessment of somatic mutation detection on reference materials with mismatch repair and proofreading deficiency. Journal of Advanced Research 2022. [DOI: 10.1016/j.jare.2022.03.016] [Reference Citation Analysis]